CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 218 enrolled
Drug / intervention
LY2951742 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01625988
NCT01625988Phase 2Completed
CompareCT.gov

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Migraine

Eli Lilly and Company·interventional·Posted Jun 22, 2012·Updated Jan 9, 2020

In Brief

A Phase 2 clinical trial evaluating LY2951742 and Placebo for Migraine Headache. Completed, enrolled 218 participants across 37 sites.

Detailed Summary

To assess the efficacy and safety of LY2951742 in the prevention of migraine headache in migraineurs with or without aura during 3 months of treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine Headache
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 22, 2012
Enrollment StartJun 28, 2012
Primary CompletionJul 1, 2013
Study CompletionSep 18, 2013
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 14.0 years ago

Interventions

LY2951742drug

Placebodrug